The majority shareholders of Laboratorios Farmacéuticos Rovi, S.A. increase their interest in ROVI to 35,383,462 shares
1 min
27 May, 2019
Operating income, growth figures, profitability and how our products have behaved
0 min
08 May, 2019
Summary of financial results for the first quarter of 2019
5 min
08 May, 2019
Advanced Final Results from the Pivotal Study of its Once-monthly Injectable Antipsychotic show that Primary and Key...
4 min
19 Mar, 2019
Operating income, growth figures, profitability and how our products have behaved.
0 min
26 Feb, 2019
Full year 2018 financial results
5 min
26 Feb, 2019
These rights will allow ROVI to distribute the product in Spain, in its different pharmaceutical forms, under the...
2 min
15 Feb, 2019
ROVI will pay Hexal nine million euros for the product, the net sales of which totalled close to 3.5 million euros in...
1 min
09 Jan, 2019
Operating income, growth figures, profitability and how our products have behaved.
0 min
06 Nov, 2018